Biological response modifiers: the new immunotherapy.
Foon
K A
KA
Division of Clinical Immunology, Roswell Park Memorial Institute, Buffalo, New York 14263.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D003115:Colony-Stimulating Factors; D000922:Immunotoxins; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons